Roche’s virtual event on key Evrysdi data presented at the 2021 CureSMA Annual Meeting
Agenda
JEWELFISH
RAINBOWFISH
Q&A
Safety, pharmacodynamic and exploratory efficacy data in non-naïve patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam
A study of risdiplam in infants with presymptomatic spinal muscular atrophy (SMA) Kathryn Wagner, M.D. Ph.D., Vice President of Neuromuscular Disorders Clinical Development
Kathryn Wagner, M.D. Ph.D., Vice President of Neuromuscular Disorders Clinical Development Paulo Fontoura, M.D. Ph.D., Global Head of Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases Clinical Development Simona Skerjanec, Therapeutic Area Head Neuroscience and Rare Diseases, Global Product Strategy Kavita Patel, Lifecycle Leader SMA, Global Product Strategy

Please register to access the replay*

*Privacy notice

Live webinar

Roche has hosted a virtual event on Monday, 14th June 2021.

Investors
Past IR Events
View more Events

Downloads

Related links